Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
Leena Gandhi
No relevant relationships to disclose
Jean-Charles Soria
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Richard Bryce
Employment or Leadership Position - Puma Biotechnology
Benjamin Besse
No relevant relationships to disclose